Maksyutov Rinat Amirovich

Maksyutov Rinat Amirovich

Education

In 2003 he graduated from Novosibirsk State University with a degree in biology.

Career

2001-2016

From 2001 to 2016, he worked as a senior laboratory assistant, research trainee, junior researcher, researcher, senior researcher, head of the laboratory of the Department of Genomic Research and Development of Methods for DNA Diagnostics of Poxviruses of the National Research Center of the WB "Vector."

In 2010, he became a laureate of the Academician Lev Sandakhchiev Prize for young scientists. His work was devoted to the creation of a candidate vaccine against smallpox.

In August 2016, he was appointed Deputy Director General for Research at the Vector Center. In the same year he took the post of general director of the institution.

2023: Dismissal from the post of head of the Research Institute "Vector"

On May 17, 2023, it became known about the dismissal of Rinat Maksyutov, Director General of the State Scientific Center for Virology and Biotechnology "Vector." According to Kommersant Siberia, one of the grounds for dismissal was "failure to take measures to resolve and prevent conflicts of interest."

The order to dismiss Mr. Maksyutov was signed by the head of Rospotrebnadzor Anna Popova on May 16, 2023. The employment contract with the director of "Vector" will be terminated on May 18, 2023, the newspaper clarifies. As a source familiar with the situation told Interfax, Rinat Maksyutov was dismissed from the Vector Research Institute due to loss of confidence.

The press service of "Vector" noted that the center is subordinate to Rospotrebnadzor and only he can comment on all personnel issues, reports the NGS edition. According to the head of the press service Nikita Kanshin, "Vector" will continue to fulfill its obligations and scientists in "Vector" "both worked and will work."

Vector is one of the largest scientific virological and biotechnological centers in Russia. The smallpox virus is stored there and vaccines are being developed. In particular, the center has created a vaccine against the coronavirus COVID-19 "EpiVacCorona."^[1]

Notes